Drug Discovery– tag –
-
Complete Series | From Beginner to Expert: Bispecific Antibody Drug Series — Full Index and Final Overview
This series, “From Beginner to Expert: Bispecific Antibody Drug,” was designed to provide a systematic understanding of bispecific antibody drugs from the fundamentals to advanced specialist-level issues. Rather than stopping at fragment... -
From Beginner to Expert | Bispecific Antibody Drug Series B6: The Technological Evolution and Historical Path of Improvement in Bispecific Antibody Drugs
Bispecific antibody drugs are now discussed as one of the important modalities in cancer therapy. However, this field did not begin in anything close to its current level of maturity. Its history is better understood as a long period in ... -
From Beginner to Expert | Bispecific Antibody Drug Series A6: What Is Likely to Grow Next? A Map of Next-Generation Bispecific Antibody Drugs
Bispecific antibody drugs are already beginning to establish a distinct clinical presence, especially in hematologic malignancies, and are starting to build their own place within cancer therapy. However, this field is far from a complet... -
From Beginner to Expert | Bispecific Antibody Drug Series B5: How Should We Think About Clinical Development Strategy and Indication Expansion?
Bispecific antibody drugs are a modality in which theoretical appeal alone is not enough; where and how clinical development begins is critically important. As we have seen from A1 through A5 and B1 through B4, this field is shaped by st... -
From Beginner to Expert | Bispecific Antibody Drug Series A5: Where Do Bispecific Antibody Drugs Sit Within the Overall Landscape of Cancer Therapy?
Bispecific antibody drugs have gained a strong presence within cancer therapy over the past several years. However, to truly understand this field, it is not enough to look at bispecific antibody drugs in isolation. What matters is to pl... -
From Beginner to Expert | Bispecific Antibody Drug Series B4: How Should We Think About Toxicity, PK/PD, and Development Bottlenecks?
Bispecific antibody drugs are a modality that often looks highly attractive in theory. Because they can handle two targets within a single molecule, they can aim for pharmacological effects that are difficult to achieve with single-targe... -
From Beginner to Expert | Bispecific Antibody Drug Series A4: Why Do Adverse Effects Occur? Understanding the Balance Between Efficacy and Safety
Bispecific antibody drugs are a modality with enormous promise in cancer therapy. As we have seen from A1 through B3, the strength of this field lies in the ability of a single molecule to engage two targets or conditions and achieve pha... -
From Beginner to Expert | Bispecific Antibody Drug Series B3: How Differences in Modality Shape Pharmacological Properties
When we look at bispecific antibody drugs, it becomes clear that even though they are grouped under the same label, they can behave very differently as actual medicines. One molecule may show very strong cell-bridging activity while stru... -
From Beginner to Expert | Bispecific Antibody Drug Series A3: What Types Are There? Classification and the Overall Landscape of Bispecific Antibody Drugs
Bispecific antibody drugs are often discussed as if they were a single technological field. In reality, however, their internal diversity is substantial. As we saw in A1, the essence of bispecific antibody drugs is to connect two targets... -
From Beginner to Expert | Bispecific Antibody Drug Series B2: What Determines Target Design and the Optimization of Mechanism of Action?
When people think about the design of bispecific antibody drugs, they often focus first on which targets should be combined. That is natural, because the value of bispecific antibody drugs arises from handling two targets at the same tim... -
From Beginner to Expert | Bispecific Antibody Drug Series A1: What Are Bispecific Antibody Drugs? A Thorough Introduction from the Basics
Bispecific antibody drugs are now one of the most important themes in the evolution of cancer therapy and antibody therapeutics. Over the past several years, they have rapidly increased in prominence. In hematologic malignancies, they ar... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A3: Why Solid Tumors Are Hard for CAR-T — The 3 Core Barriers [Beginner]
New here?→ A0: What is CAR-T therapy? The big picture + index→ A1: Where CAR-T is used today (blood cancers first) Deep dive next (B3): next-gen CAR engineering to overcome these barriers (multi-target, logic-gated, armored, local delive... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B2: Toxicity Management, Site Operations & Long-Term Safety (Including Regulatory Logic) [Expert]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A2: CAR-T side effects without panic (what happens, what to monitor) “CAR-T Toxicity Management: Timeline × Actions × Follow-Up”Left: Day 0–14 (CRS/... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A2: CAR-T Side Effects Without Panic — What Can Happen & What to Monitor [Beginner]
New here? Start with the basics and where CAR-T is used today.→ A0: What Is CAR-T Therapy? The Big Picture + Series Index→ A1: Where CAR-T Is Used Today — Blood Cancers First Want the deep dive (B2)? We will cover severity grading concep... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B1: FDA-Approved CAR-T Landscape (Products, Targets, Companies, Label Logic) [Expert]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A1: Where CAR-T is used today (blood cancers first) Executive summary FDA-approved oncology CAR-T products cluster around two core targets: CD19 (B-... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A1: Where CAR-T Is Used Today — The Big Picture (Blood Cancers First) [Beginner]
New here? If you haven’t read the introduction, it will make this post much easier to follow.→ A0: What Is CAR-T Therapy? The Big Picture + Series Index Want the deep dive? The expert post (B1) will organize FDA-approved CAR-T products b... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A0: What Is CAR-T Therapy? The Big Picture, in Plain Language [Beginner]
How to use this series (two-layer linkage: Beginner → Expert) This series explains CAR-T therapy in a stepwise way so that readers who are new to the term can first grasp the big picture (Layer A), and then move to the expert layer (Laye... -
Oncology Drug Approval News Flash FDA approves teclistamab (Tecvayli) plus daratumumab hyaluronidase-fihj for relapsed/refractory multiple myeloma (and converts Tecvayli monotherapy from accelerated to traditional approval)
On March 5, 2026, the U.S. FDA approved teclistamab (Tecvayli), a BCMA×CD3 bispecific antibody, in combination with daratumumab hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma (RRMM) who have received at least ... -
Oncology Drug Approval News Flash: Encorafenib plus cetuximab and fluorouracil-based chemotherapy receives traditional FDA approval for BRAF V600E–mutated metastatic colorectal cancer
FDA approval summary On February 24, 2026, the U.S. Food and Drug Administration (FDA) granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorourac... -
Oncology Drug Approval News Flash: Optune Pax, a low electric field tumor treating fields device, approved with gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer
FDA approval summary On February 11, 2026, the U.S. Food and Drug Administration (FDA) approved a low electric field generator device, Optune Pax (Novocure), in combination with gemcitabine and nab-paclitaxel for the treatment of adult p...
